COVAX-19Ⓡ Vaccine: Completely blocks virus transmission to non-immune individuals

Vivek P. Chavda*, Lalitkumar K. Vora, Disha R.Vihol

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

1024 Downloads (Pure)


Various vaccine platforms are geared against COVID-19 vaccine development to produce immunogens in cells. To design a recombinant protein-based COVID-19 vaccine, Vaxine pty Ltd used computer models of the spike protein and its human receptor, ACE2, to identify how the virus infects human cells. Based on this, the COVAX-19Ⓡ vaccine is synthesized. It does reduce not only COVID-19 disease but also blocks virus shedding and transmission. Researchers are optimistic that this vaccine candidate could be clinically available soon with sufficient vaccine efficacy with a considerable amount of reduction in vaccination-related side effects.
Original languageEnglish
Article number100004
Number of pages4
JournalClinical Complementary Medicine and Pharmacology
Issue number1
Early online date09 Aug 2021
Publication statusPublished - Dec 2021


Dive into the research topics of 'COVAX-19Ⓡ Vaccine: Completely blocks virus transmission to non-immune individuals'. Together they form a unique fingerprint.

Cite this